Study wrapper · #946
The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.
Hudanich M, Smith SN, Marino A, et al. Cureus. 2025.
DOI: 10.7759/cureus.93104PubMed: 41141001
Editor's note
This scoping review examines incretin mimetics as a possible option for insulin resistance in PCOS, reporting improvements in weight and insulin sensitivity across GLP-1, dual, and triple agonists. The evidence is early and heterogeneous, and the authors call for research into mechanisms and optimal use. A useful signal for an off-label application that warrants cautious framing.
Plain-language abstract
A scoping review found that GLP-1-based agents, including semaglutide, tirzepatide, and retatrutide, were associated with improvements in weight and insulin sensitivity in women with polycystic ovarian syndrome compared with standard therapy.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026